PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies. Annually, more than 10 million prenatal risk assessments are made on the basis of PerkinElmer tests.

PerkinElmer is developing the Vanadis® NIPT system which is an automated non-sequencing, non-PCR based solution for cfDNA analysis. PerkinElmer will in the future offer an easy to use, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.

PerkinElmer was chosen as the principal screening partner for ASPRE. Throughout the study, the PerkinElmer DELFIA® Xpress PlGF 1-2-3TM assay was used as an aid in screening for pre-eclampsia in conjunction with maternal history, mean arterial blood pressure (MAP) measurement, and UTPi (Uterine Artery Doppler). ASPRE results were published in June 2017 and demonstrated that early screening helps significantly reduce the incidence of preterm pre-eclampsia.

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.